The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessment of pathologic response in the colorectal cancer cohort of the IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors.
 
Frederic Bibeau
Honoraria - BMS; GlaxoSmithKline; MSD; Pierre Fabre; Sanofi; servier
Consulting or Advisory Role - Amgen; BMS
Travel, Accommodations, Expenses - Amgen; Pierre Fabre
 
Racha Mansar
No Relationships to Disclose
 
Franck Monnien
No Relationships to Disclose
 
Aymeric De Montfort
No Relationships to Disclose
 
Ellen Blanc
No Relationships to Disclose
 
Clélia Coutzac
Honoraria - Amgen; AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; Merck Serono; MSD Oncology; SERVIER
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; SERVIER
Speakers' Bureau - Amgen; Merck Serono; SERVIER
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Mundipharma; Sandoz; SERVIER
 
Christelle De La Fouchardiere
Consulting or Advisory Role - Amgen; Astellas Pharma; BeiGene; Bristol-Myers Squibb; Daichi-Sankyo; Gilead Sciences; Jazz Pharmaceuticals; MSD Oncology; Pierre Fabre; Roche/Genentech; SERVIER; Takeda
Research Funding - Agenus (Inst); MSD (Inst); Pierre Fabre (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD Oncology; Pierre Fabre; SERVIER